Latest News - Movement Disorders

Wednesday, July 18, 2018

Investigational Tau Modifier Receives Orphan Drug Status for Progressive Supranuclear Palsy

The Food and Drug Administration (FDA) has granted an orphan drug designation to ASN120290 (Asceneuron SA, Lausanne, Switzerland) for the treatment of progressive supranuclear palsy (PSP). In preclini…

Read the full story

Friday, July 13, 2018

IncobotulinumtoxinA Approved for Treatment of Excessive Drooling

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for incobotulinumtoxin A (Xeomin; Merz, Raleigh, NC) for the treatment of chronic sialorrhea, …

Read the full story

Friday, June 29, 2018

New Dosing Formulation and Strength for Pimavanserin Approved

The Food and Drug Administration (FDA) has approved a new capsule dose formulation and a new tablet strength of pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA). Both the new dose and th…

Read the full story

Tuesday, June 26, 2018

New Monoclonal Antibodies Against Alpha-Synuclein Generated

ProMIS Neurosciences, Inc has announced that numerous antibodies against toxic oligomers of alpha-synuclein, implicated in Parkinson’s disease (PD) have begun the final stage of discovery. Hundr…

Read the full story

Wednesday, June 20, 2018

Impulse Control Disorders More Common in People Who Take Dopamine Agonists

A French study which followed 411 people for an average of three years who had been diagnosed with Parkinson’s disease (PD) within 5 years, has reported an increase in impulse control disorders …

Read the full story

Wednesday, June 13, 2018

Medtronic Deep Brain Stimulation Clinician Programmer Receives FDA Approval

Medtronic announced that the Food and Drug Administration (FDA) had recently approved its Deep Brain Stimulation (DBS) Clinician Programmer and Activa Programming Application. The Activa Programming A…

Read the full story

Wednesday, June 13, 2018

Risk for Parkinson’s Disease May Be Linked to an Earlier Diagnosis of Diabetes

A study from England published online in Neurology on June 13 suggests that people with type 2 diabetes may have an increased risk of developing Parkinson’s disease (PD) later in …

Read the full story

Monday, June 04, 2018

Medicare Benefit Coverage Available for MR-Guided Focused Ultrasound to Treat Essential Tremor

Magnetic resonance (MR)-guided focused ultrasound (MRgFUS) (INSIGHTEC, Miami, FL) for the treatment of essential tremor is now available as a medicare benefit in 10 states: Connecticut, Maine, New Ham…

Read the full story

Friday, June 01, 2018

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regarding new “right-to-…

Read the full story

Friday, May 25, 2018

DaxibotulinumtoxinA Has a 24-Week Effect for Treatment of Cervical Dystonia

Phase 2 clinical trial study data for daxibotulinumtoxinA (RT002; Revance, Newark, CA) for treatment of cervical dystonia (CD) were published in the journal Movement Disorders. The data show that daxi…

Read the full story

Thursday, May 10, 2018

Retinal Deposits of Phosphorylated Alpha-Synuclein: A Biomarker for Parkinson’s Disease?

Analysis of retinas from 19 autopsied subjects, 9 with Parkinson’s disease (PD), and 4 with incidental Lewy body disease, showed accumulation of phosphorylated α‐synuclein (AS) that was …

Read the full story

Tuesday, May 08, 2018

Amantadine-Extended Release: Different Pharmocokinetics Drive Different Clinical Effects

Amantadine-ER (Gocovri; Adamas, Emeryville, CA) is approved by the Food and Drug Administration (FDA) for treatment of dyskinesia in patients with Parkinson’s disease taking levodopa therapy wit…

Read the full story

Monday, May 07, 2018

Nonmotor Symptoms of Parkinson’s Disease Underreported and Undertreated

More than 2 in 3 patients with Parkinson’s disease (PD) or their caregivers affirm the presence of nonmotor symptoms that significantly and negatively affect their quality of life. Of 3,500 peop…

Read the full story

Monday, April 30, 2018

Treating Patients With Essential Tremor with Wristwatch-Style Neuromodulation

Using a wrist-worn neuromodulation device (Cala Health Inc, Burlingame, CA) that stimulates the radial and median nerves, people with essential tremor may find some relief from a new, noninvasive type…

Read the full story

Thursday, April 26, 2018

OnabotulinumtoxinA: Safety and Efficacy for Treating Children With Spasticity in Cerebral Palsy

At the American Academy of Neurology (AAN), researchers Heakyung Kim, Jill Meilahn, Chengcheng Liu, Henry G. Chambers, and Rozalina Dimitrova presented results evaluating the efficacy and safety of on…

Read the full story
Load More